Clinical considerations in MCL management: frailty assessment, the multidisciplinary team & managing the use of BTKis

This VJHemOnc podcast explores the evolving management of mantle cell lymphoma (MCL), from assessing patient fitness to sequencing therapy after BTK inhibitor progression. Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, and Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, discuss assessing fitness and frailty, while Craig Portell, MD, University of Virginia, Charlottesville, VA, outlines the multidisciplinary approach to MCL care. Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, reviews frontline sequencing, including using MRD status to guide transplant decisions, and Dr Phillips and Dr Portell discuss managing patients with higher-risk disease features. Dr Portell also addresses toxicity and treatment burden with long-term BTK inhibitor use. To conclude, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Dr Karimi highlight emerging options after BTK inhibitor progression, including non-covalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, and bispecific antibodies.